Migdal Insurance & Financial Holdings Ltd. Cellectis S.A. Transaction History

Migdal Insurance & Financial Holdings Ltd.

$5.99 Billion
Q2 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 04, 2021	SELL	$14.36 - $20.93 $333,496 - $486,078	-23,224 Closed	0 $0
Q1 2021 May 04, 2021	BUY	$18.19 - $33.25 $262,154 - $479,199	14,412 Added 163.55%	23,224 $469,000
Q4 2020 Feb 08, 2021	BUY	$15.87 - $31.64 $139,846 - $278,811	8,812 New	8,812 $238,000

Others Institutions Holding CLLS

# of Institutions

Shares Held

11.2M

Call Options Held

2.8K

Put Options Held

17.9K

Long Focus Capital Management, LLC San Juan, PR

4.62M
Shares

$8.4 Million
0.35% of portfolio
Capital International Investors Los Angeles, CA

1.85M
Shares

$3.36 Million
0.0% of portfolio
Credit Suisse Ag Zurich, V8

1.44M
Shares

$2.62 Million
0.0% of portfolio
Ubs Asset Management Americas Inc Chicago, IL

1.44M
Shares

$2.62 Million
0.0% of portfolio
Baillie Gifford & CO

708K
Shares

$1.29 Million
0.0% of portfolio

View Full List

About Cellectis S.A.

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $82.8M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

More about CLLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Migdal Insurance & Financial Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Migdal Insurance & Financial Holdings Ltd. with notifications on news.

Account